Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | BMC Cancer

Figure 2

From: Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy

Figure 2

PAF receptor antagonist reduces PGE2, VEGF and NO levels in the ascitis fluid. EAT cells (1 × 105) were inoculated i.p. into BALB/c mice and the levels of PGE2, VEGF and nitric oxide (NO) were measured in the ascitis fluid 7 days later. One group of mice was treated with WEB2170 (5 mg/Kg), 30 min before tumour implantation and daily up to the 6th day. Data represent the mean ± SEM (n = 3-7). Statistical analyses were performed using ANOVA and SNK (Student Neumans-Keuls test) and differences were considered significant at p < 0.05. (*) p < 0.05 compared to non-treated group. In each graph, the first column represents the baseline levels, determined in the washings of the peritoneal cavity of mice without tumours, the second column represents the levels in tumour-bearing mice without treatment (PBS-control group), and the third column represents tumour-bearing mice treated with WEB2170.

Back to article page